

28 November 2023

UMW (UMWH MK)

Sime Darby's Offer Remains Attractive

- Still NEUTRAL, with MYR5 TP and 2% upside. UMW's 3Q23 earnings exceeded our expectations, with stronger-than-expected manufacturing & engineering (M&E) and automotive segments. Toyota and Perodua's order backlogs further soften, supporting our expectation that 2024 will likely see dampening car sales. We remain NEUTRAL as we lack visibility on 2024's car sales, and as Sime Darby's (SIME MK, BUY, TP: MYR2.85) offer price of MYR5 to acquire UMW only has 2% upside.
- **Results beat expectations.** UMW's 3Q23 core net profit of MYR163m brought 9M23 core net profit to MYR401m, making up 89% of ours and Street's full-year estimate. The deviation was mainly due to stronger-than-expected M&E and automotive segments.
- **Results highlights.** Automotive PBIT rose 21% QoQ on the back of higher sales volumes of both Toyota and Perodua (+19% and 34%). Toyota's and Perodua's 9M23 sales volumes of 76.5k and 233.2k make up 77% and 73% of our FY23 volume assumptions. Its M&E unit, on the other hand, recorded an 18% QoQ increase in PBIT on the back of stronger contributions from auto-components, lubricants, and aerospace sub-segments.
- **Outlook.** Toyota's order backlog stands at 34k units (52k at end-May and 40k at end-Aug), while Perodua's is at 140k units (190k at end-May and 140k at end-Aug). Perodua has revised its sales goal to 325k (slightly above our 320k forecast) and hence, we anticipate a robust final push from the national carmaker in the next two months, which may spill over to early next year. However, further order backlogs' softening is anticipated, considering the lack of new catalysts to support such high levels.
- We revise our FY23-FY25 forecasts higher by 3-14%. We increased our car ASP forecasts for both Toyota and Perodua as well as M&E revenue growth assumptions, as we believe our previous assumptions were too conservative.
- We maintain our call and TP, based on 14x P/E on FY24F EPS which matches SIME's offer price to acquire UMW. We believe the offer price is attractive considering it is above UMW's historical mean P/E of 12x. Our TP includes 0% ESG adjustments. We are NEUTRAL on UMW as the FY24 outlook remains uncertain, and SIME's offer price has less than 10% upside from the current share price.
- **Key downside risks include** SIME's proposed acquisition falling through, and lower-than-expected orders, deliveries, and margins. The opposite represents upside risks.

Forecasts and Valuation	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Total turnover (MYRm)	11,061	15,814	17,469	14,876	14,975
Recurring net profit (MYRm)	226	399	514	416	408
Recurring net profit growth (%)	(20.6)	76.5	28.7	(19.0)	(2.0)
Recurring P/E (x)	25.29	14.33	11.14	13.75	14.03
P/B (x)	1.4	1.3	1.2	1.1	1.0
P/CF (x)	21.90	6.93	17.81	9.96	10.48
Dividend Yield (%)	1.2	2.9	3.1	2.8	2.8
EV/EBITDA (x)	27.32	3.76	3.18	3.56	3.00
Return on average equity (%)	(4.5)	9.9	11.2	8.3	7.5
Net debt to equity (%)	net cash				

Source: Company data, RHB

Consumer Cyclical | Auto & Autoparts

Neutral (Maintained)


Target Price (Return):	MYR5 (2.0%)
Price (Market Cap):	MYR4.90 (USD1,223m)
ESG score:	3.0 (out of 4)
Avg Daily Turnover (MYR/USD)	10.2m/2.17m

Analyst

Syahril Hanafiah +603 9280 8879 syahril.hanafiah@rhbgroup.com

Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	41.2	1.2	3.4	33.9	46.7
Relative	44.4	0.8	3.1	30.7	49.3
52-wk Price low	//high (MYR))		3.25	- 4.92



Overall ESG Score: 3.0 (out of 4)

E: GOOD

UMW has taken efforts to monitor and improve its environmental standing, especially with energy consumption, carbon emissions, and water management. Its carbon footprint increased 2.36% in FY19. S: GOOD

Aside from the up-to-date health & safety policies and guidelines, UMW is also consistent in its CSR participation – achieving 9,241 volunteer hours in 2019. It recorded average training hours of 12.36 hours per employee in FY19.

G: GOOD

Management has held regular engagements with the market and media while adhering to Global Reporting Initiative Sustainability Reporting standards and principles.



Financial Exhibits

Consumer Cyclical | Auto & Autoparts

Financial summary (MYR)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Recurring EPS	0.19	0.34	0.44	0.36	0.35
DPS	0.06	0.14	0.15	0.14	0.14
BVPS	3.43	3.72	4.12	4.46	4.80
Return on average equity (%)	(4.5)	9.9	11.2	8.3	7.5
					Dec-25F
,					14.03
					1.0
. ,					2.6
. ,					2.8
.,					3.00
EV/EBI1 (X)	na		4.92	5.83	4.84
Income statement (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Total turnover	11,061	15,814	17,469	14,876	14,975
Gross profit	1,194	2,806	3,218	2,651	2,704
EBITDA	172	946	1,134	879	906
Depreciation and amortisation	(344)	(341)	(402)	(342)	(344)
Operating profit	(171)	606	733	537	561
Net interest	(108)	(114)	(93)	(93)	(93)
Pre-tax profit	37	896	1,116	836	832
Taxation	33	(219)	(282)	(161)	(168)
Reported net profit	(177)	415	514	416	408
Recurring net profit	226	399	514	416	408
Cash flow (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Change in working capital	(221)	0	(280)	47	(4)
Cash flow from operations	261	825	321	575	546
Capex	(406)	(507)	(800)	(400)	(400)
Cash flow from investing activities	12	(507)	(416)	(100)	(129)
Dividends paid	(68)	(166)	(175)	(158)	(158)
Cash flow from financing activities	(275)	(196)	(205)	(188)	(188)
Cash at beginning of period	2,051	2,941	2,808	2,508	2,795
Net change in cash	(2)	122	(300)	287	230
Ending balance cash	2,057	3,064	2,508	2,795	3,025
Balance sheet (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
					3,025
•					2,958
•	2,524	2,655	2,655	2,655	2,655
Total investments					
Total investments Total assets			12,898	12,635	12.878
Total assets	12,173	12,417	12,898 225	12,635 225	12,878 225
Total assets Short-term debt	12,173 655	12,417 225	225	225	225
Total assets Short-term debt Total long-term debt	12,173 655 2,133	12,417 225 1,379	225 1,379	225 1,379	225 1,379
Total assets Short-term debt Total long-term debt Total liabilities	12,173 655 2,133 5,410	12,417 225 1,379 5,277	225 1,379 5,543	225 1,379 5,071	225 1,379 5,109
Total assets Short-term debt Total long-term debt Total liabilities Total equity	12,173 655 2,133 5,410 6,763	12,417 225 1,379 5,277 7,140	225 1,379 5,543 7,355	225 1,379 5,071 7,564	225 1,379 5,109 7,768
Total assets Short-term debt Total long-term debt Total liabilities	12,173 655 2,133 5,410	12,417 225 1,379 5,277	225 1,379 5,543	225 1,379 5,071	225 1,379 5,109
Total assets Short-term debt Total long-term debt Total liabilities Total equity	12,173 655 2,133 5,410 6,763	12,417 225 1,379 5,277 7,140	225 1,379 5,543 7,355	225 1,379 5,071 7,564	225 1,379 5,109 7,768 12,878
Total assets Short-term debt Total long-term debt Total liabilities Total equity Total liabilities & equity	12,173 655 2,133 5,410 6,763 12,173	12,417 225 1,379 5,277 7,140 12,417	225 1,379 5,543 7,355 12,898	225 1,379 5,071 7,564 12,635	225 1,379 5,109 7,768
Total assets Short-term debt Total long-term debt Total liabilities Total equity Total liabilities & equity Key metrics	12,173 655 2,133 5,410 6,763 12,173 Dec-21	12,417 225 1,379 5,277 7,140 12,417 Dec-22	225 1,379 5,543 7,355 12,898 Dec-23F	225 1,379 5,071 7,564 12,635 Dec-24F	225 1,379 5,109 7,768 12,878 Dec-25F
Total assets Short-term debt Total long-term debt Total liabilities Total equity Total liabilities & equity Key metrics Revenue growth (%)	12,173 655 2,133 5,410 6,763 12,173 Dec-21 15.8	12,417 225 1,379 5,277 7,140 12,417 Dec-22 43.0	225 1,379 5,543 7,355 12,898 Dec-23F 10.5	225 1,379 5,071 7,564 12,635 Dec-24F (14.8)	225 1,379 5,109 7,768 12,878 Dec-25F 0.7
Total assets Short-term debt Total long-term debt Total liabilities Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurrent EPS growth (%)	12,173 655 2,133 5,410 6,763 12,173 Dec-21 15.8 (20.6)	12,417 225 1,379 5,277 7,140 12,417 Dec-22 43.0 76.5	225 1,379 5,543 7,355 12,898 Dec-23F 10.5 28.7	225 1,379 5,071 7,564 12,635 Dec-24F (14.8) (19.0)	225 1,379 5,109 7,768 12,878 Dec-25F 0.7 (2.0) 18.1
Total assets Short-term debt Total liabilities Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurrent EPS growth (%) Gross margin (%)	12,173 655 2,133 5,410 6,763 12,173 Dec-21 15.8 (20.6) 10.8 1.6	12,417 225 1,379 5,277 7,140 12,417 Dec-22 43.0 76.5 17.7	225 1,379 5,543 7,355 12,898 Dec-23F 10.5 28.7 18.4	225 1,379 5,071 7,564 12,635 Dec-24F (14.8) (19.0) 17.8	225 1,379 5,109 7,768 12,878 Dec-25F 0.7 (2.0) 18.1 6.0
Total assets Short-term debt Total liabilities Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurrent EPS growth (%) Gross margin (%) Operating EBITDA margin (%)	12,173 655 2,133 5,410 6,763 12,173 Dec-21 15.8 (20.6) 10.8 1.6 (1.6)	12,417 225 1,379 5,277 7,140 12,417 Dec-22 43.0 76.5 17.7 6.0	225 1,379 5,543 7,355 12,898 Dec-23F 10.5 28.7 18.4 6.5	225 1,379 5,071 7,564 12,635 Dec-24F (14.8) (19.0) 17.8 5.9	225 1,379 5,109 7,768 12,878 Dec-25F 0.7 (2.0)
Total assets Short-term debt Total liabilities Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurrent EPS growth (%) Gross margin (%) Operating EBITDA margin (%)	12,173 655 2,133 5,410 6,763 12,173 Dec-21 15.8 (20.6) 10.8 1.6	12,417 225 1,379 5,277 7,140 12,417 Dec-22 43.0 76.5 17.7 6.0 2.6	225 1,379 5,543 7,355 12,898 Dec-23F 10.5 28.7 18.4 6.5 2.9	225 1,379 5,071 7,564 12,635 Dec-24F (14.8) (19.0) 17.8 5.9 2.8	225 1,379 5,109 7,768 12,878 Dec-25F 0.7 (2.0) 18.1 6.0 2.7
	Recurring EPS DPS BVPS Return on average equity (%) Valuation metrics Recurring P/E (x) P/B (x) FCF Yield (%) Dividend Yield (%) EV/EBITDA (x) EV/EBITDA (x) EV/EBIT (x) Income statement (MYRm) Total turnover Gross profit EBITDA Depreciation and amortisation Operating profit Net interest Pre-tax profit Taxation Reported net profit Recurring net profit Cash flow (MYRm) Change in working capital Cash flow from operations Capex Cash flow from financing activities Dividends paid Cash flow from financing activities Cash flow from financing activities Dividends paid Cash at beginning of period Net change in cash Ending balance cash Balance sheet (MYRm) Total cash and equivalents Tangible fixed assets	Recurring EPS 0.19 DPS 0.06 BVPS 3.43 Return on average equity (%) (4.5) Valuation metrics Dec-21 Recurring P/E (x) 25.29 P/B (x) 1.4 FCF Yield (%) (2.5) Dividend Yield (%) 1.2 EV/EBITDA (x) 27.32 EV/EBITDA (x) 27.32 EV/EBIT (x) na Income statement (MYRm) Dec-21 Total turnover 11,061 Gross profit 1,194 EBITDA 172 Depreciation and amortisation (344) Operating profit (171) Net interest (108) Pre-tax profit 37 Taxation 33 Reported net profit (177) Recurring net profit (221) Cash flow (MYRm) Dec-21 Change in working capital (221) Cash flow from operations 261 Capex (406) Cash flow from inv	Recurring EPS 0.19 0.34 DPS 0.06 0.14 BVPS 3.43 3.72 Return on average equity (%) (4.5) 9.9 Valuation metrics Dec-21 Dec-22 Recurring P/E (x) 25.29 14.33 P/B (x) 1.4 1.3 FCF Yield (%) (2.5) 5.6 Dividend Yield (%) 1.2 2.9 EV/EBITDA (x) 27.32 3.76 EV/EBIT (x) na 5.88 Income statement (MYRm) Dec-21 Dec-22 Total turnover 11,061 15,814 Gross profit 1,194 2,806 EBITDA 172 946 Depreciation and amortisation (344) (341) Operating profit (171) 606 Net interest (108) (114) Pre-tax profit 37 896 Taxation 33 (219) Recurring net profit (177) 415 Recurring net p	Recurring EPS 0.19 0.34 0.44 DPS 0.06 0.14 0.15 BVPS 3.43 3.72 4.12 Return on average equity (%) (4.5) 9.9 11.2 Valuation metrics Dec-21 Dec-22 Dec-23F Recurring P/E (x) 25.29 14.33 11.14 P/B (x) 1.4 1.3 1.2 FCF Yield (%) (2.5) 5.6 (8.4) Dividend Yield (%) 1.2 2.9 3.1 EV/EBITDA (x) 27.32 3.76 3.18 EV/EBIT (x) na 5.88 4.92 Income statement (MYRm) Dec-21 Dec-22 Dec-23F Total turnover 11.061 15.814 17.469 Gross profit 1,194 2,806 3,218 EBITDA 172 946 1,134 Depreciation and amortisation (344) (341) (493) Operating profit (177) 416 733 Net int	Recurring EPS 0.19 0.34 0.44 0.36 DPS 0.06 0.14 0.15 0.14 BVPS 3.43 3.72 4.12 4.46 Return on average equity (%) (4.5) 9.9 11.2 8.3 Valuation metrics Dec-21 Dec-22 Dec-23F Dec-24F Recurring P/E (x) 25.29 14.33 11.14 13.75 P/B (x) 1.4 1.3 1.2 1.1 FCF Yield (%) (2.5) 5.6 (8.4) 3.1 Dividend Yield (%) 1.2 2.9 3.1 2.8 EV/EBITO (x) 27.32 3.76 3.18 3.56 EV/EBIT (x) na 5.88 4.92 5.83 Income statement (MYRm) Dec-21 Dec-22F Dec-24F Total turnover 11.061 15.814 17.469 14.876 Gross profit 1.194 2.806 3.218 2.651 EBITDA 172 946 1.134

Source: Company data, RHB



Consumer Cyclical | Auto & Autoparts

Results At a Glance

Figure 1: Results review

FYE Dec	3Q22	2Q23	3Q23	QoQ	YoY	9M22	9M23	YoY	Comments
(MYRm)				(%)	(%)			(%)	
Revenue	4,057	4,485	4,834	8	19	11,439	13,699	20	Higher YoY due to better performances across all segments
EBIT	163	402	202	(50)	23	450	732	63	-
Finance costs	(21)	(16)	(16)	(2)	(26)	(86)	(47)	(45)	
Investment income	17	21	25	16	49	46	74	60	
Associates	73	69	116	68	59	267	294	10	Higher YoY due to higher sales volumes by Perodua
Pretax profit	231	476	326	(31)	41	678	1,053	55	PBT increased by 3%, mainly lifted by Toyota's higher PBT, partially attributable to lower derivative mark-to-market losses.
Tax	(72)	(91)	(66)	(27)	(9)	(172)	(204)	18	
MI	(41)	(64)	(70)	8	69	(144)	(186)	29	
Core net profit	96	115	163	42	69	294	401	36	Due to increase in tax expenses and MI, core net profit fell 7%, despite a 3% increase in PBT.
EBIT margin (%)	4.0	9.0	4.2			3.9	5.3		
Pretax margin (%)	5.7	10.6	6.7			5.9	7.7		
Eff tax rate (%)	(31.2)	(19.0)	(20.2)			(25.4)	(19.3)		
Net margin (%)	2.4	2.6	3.4			2.6	2.9		

Source: Company data, RHB

Figure 2: Earnings review – segmental breakdown

FYE Dec	3Q22	2Q23	3Q23	QoQ	YoY	9M22	9M23	YoY	Comments
(MYRm)				(%)	(%)			(%)	
Automotive	3,428	3,417	4,023	18	17	9,615	11,067	15	Higher YoY due to higher sales volumes
Equipment	394	456	452	(1)	15	1,133	1,343	19	
Manufacturing & engineering	252	300	364	21	44	706	987	40	Higher YoY mainly due to higher sales of lubricants (+34% YoY)
Others	(17)	312	28	(91)	(266)	(14)	334	>100	Lifted by the MYR305m proceeds from the Serendah land sale in 2Q23.
Revenue	4,057	4,485	4,834	8	19	11,439	13,699	20	
Automotive	184	213	258	21	40	592	687	16	In line with increase in revenue, due to higher sales volumes for both Toyota and Perodua
Equipment	50	49	56	13	11	117	156	33	
Manufacturing & engineering	13	22	26	18	91	37	70	88	Higher YoY likely due to higher contribution from the aerospace segment
Others	(15)	192	(12)	106	19	(69)	140	(303)	
PBT	231	476	326	(31)	41	678	1,053	55	
PBT Margins									
Automotive	5.4	6.2	6.4			6.2	6.2		
Equipment	12.7	10.8	12.3			10.3	11.6		
Manufacturing & engineering	5.3	7.3	7.1			5.3	7.1		Likely due to higher aerospace contribution.

Source: Company data, RHB



28 November 2023

Consumer Cyclical | Auto & Autoparts

Figure 3: UMW's vehicle sales summary

FYE Dec	3Q22	2Q23	3Q23	QoQ	YoY	9M22	9M23	YoY	Comments
(units)				(%)	(%)			(%)	
Toyota	24,961	23,440	27,852	18.8	11.6	70,871	76,511	8.0	Toyota/Lexus' sales volume softened 7% QoQ due to a seasonally shorter quarter.
- Passenger	17,340	16,831	20,336	20.8	17.3	48,990	54,596	11.4	
- Commercial	7,621	6,609	7,516	13.7	(1.4)	21,881	21,915	0.2	
Perodua	69,011	66,126	88,537	33.9	28.3	196,354	233,227	18.8	Higher YoY as utilisation has increased to 94% in 9M23 (9M22: 78%)
- Passenger	69,011	66,126	88,537	33.9	28.3	196,354	233,227	18.8	
- Commercial	0	0	0			0	0		
Total	93,972	89,566	116,389	29.9	23.9	267,225	309,738	15.9	

Source: Company data, RHB

Figure 4: Key assumptions

FYE Dec	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Toyota/Lexus TIV (units) – current	70,009	59,320	72,394	101,034	100,000	90,000	85,000
Perodua TIV (units) – current	240,341	220,154	190,291	282,019	320,000	250,000	230,000

Source: Company data, RHB



Consumer Cyclical | Auto & Autoparts

Emissions And ESG

Trend analysis


In FY22, Scope 1 emissions increased to 8.1k tonnes of CO2 equivalents (FY21: 5.4k tonnes of CO2 equivalents) while Scope 2 increased to 46.3k tonnes of CO2 equivalents (FY21: 40.1k tonnes of CO2 equivalents)

Emissions (tCO2e)	Dec-20	Dec-21	Dec-22
Scope 1	6,772	5,398	8,069
Scope 2	38,372	40,127	46,321
Scope 3	na	na	526
Total emissions	45,144	45,525	54,916
Source: Company data, RHB			

Latest ESG-Related Developments

- Emission target: UMW intends to reduce its emissions by 5% in comparison with 2019's consumption.
- Waste management: UMW adopts the practice of 3Rs through segregation and reducing hazardous waste through oil recovery, reducing paper usage, and digitalising its operations wherever possible.

ESG Rating History



Source: RHB

Recommendation Chart



Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2023-08-25	Neutral	5.00	4.74
2023-06-01	Neutral	3.80	3.89
2023-02-28	Buy	5.00	3.90
2023-02-17	Buy	5.10	3.85
2022-11-30	Neutral	3.35	3.26
2022-08-28	Neutral	3.10	3.06
2022-07-15	Neutral	2.90	2.83
2022-05-25	Neutral	3.64	3.35
2022-03-15	Neutral	3.29	3.06
2022-02-28	Neutral	3.29	3.07
2021-11-30	Neutral	2.83	3.08
2021-08-27	Neutral	2.94	3.11
2021-07-27	Neutral	2.94	2.91
2021-05-25	Neutral	3.43	3.25
2021-04-22	Neutral	3.40	3.38

Source: RHB, Bloomberg



RHB Guide to Investment Ratings

Buy:	Share price may exceed 10% over the next 12 months
Trading Buy:	Share price may exceed 15% over the next 3 months, however longer-
	term outlook remains uncertain
Neutral:	Share price may fall within the range of +/- 10% over the next
	12 months
Take Profit:	Target price has been attained. Look to accumulate at lower levels
Sell:	Share price may fall by more than 10% over the next 12 months
Not Rated:	Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Malavsia

Save as disclosed in the following link <u>RHB Research Conflict Disclosures - Nov 2023</u> and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report. RHBIB is not a market maker in the securities or capital market products of the
- 2 subject company(ies) covered in this report.
- З. None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- 4. RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the 5 production of this report.

Thailand

- Save as disclosed in the following link <u>RHB Research Conflict Disclosures Nov 2023</u> and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
 RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHB Securities (Thailand) PCL is not a market maker in the securities or capital for the
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a 3. director or board member to f the subject company(ies) covered in this report
- 1. *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 4. months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including 5. gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link <u>RHB Research Conflict Disclosures - Nov 2023</u> and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
 - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*; Being bound by an agreement to purchase securities or has the right to
 - b) transfer the securities or has the right to pre subscribe the securities*
 - Being bound or required to buy the remaining securities that are not c) subscribed/placed out pursuant to an Initial Public Offering*.
- d) Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital 2. market products of the subject company(ies) covered in this report. None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a
- 3 director or board member* of the subject company(ies) covered in this report.
- 4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- 5. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report: Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas

Indonesia only. *The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link RHB Research Conflict Disclosures - Nov 2023 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a 1. market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its 2. analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have 4. and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any 6. compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysits.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia Tel : +603 9280 8888 Fax : +603 9200 2216

BANGKOK

Fax :+66 2088 9799

RHB Securities (Thailand) PCL 10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand Tel: +66 2088 9999

JAKARTA

PT RHB Sekuritas Indonesia Revenue Tower, 11th Floor, District 8 - SCBD JI. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia Tel : +6221 509 39 888 Fax : +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470

